Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha‐Synuclein Disease
Authors:
Open Access
- 24 December 2024
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 97 (4) , 730-740
Abstract
Objective: Remote identification of individuals with severe hyposmia may enable scalable recruitment of participants with underlying alpha‐synuclein aggregation. We evaluated the performance of a staged screening paradigm using remote smell testing to enrich for abnormal dopamine transporter single‐photon emission computed tomography imaging (DAT‐SPECT) and alpha‐synuclein aggregation.Methods: The Parkinson's Progression Markers Initiative (PPMI) recruited participants for the prodromal cohort who were 60‐years and older without a Parkinson's disease diagnosis. Participants were invited to complete a University of Pennsylvania Smell Identification Test (UPSIT) independently through an online portal. Hyposmic participants were invited to complete DAT‐SPECT, which determined eligibility for enrollment in longitudinal assessments and further biomarker evaluation including cerebrospinal fluid alpha‐synuclein seed amplification assay (aSynSAA).Results: As of January 29, 2024, 49,843 participants were sent an UPSIT and 31,293 (63%) completed it. Of UPSIT completers, 8,301 (27%) scored <15th percentile. Of 1,546 who completed DAT‐SPECT, 1,060 (69%) had DAT‐SPECT binding <100% expected for age and sex. Participants with an UPSIT <10th percentile (n = 1,221) had greater likelihood of low DAT‐SPECT binding compared to participants with an UPSIT in the 10th to 15th percentile (odds ratio, 3.01; 95% confidence interval, 1.85–4.91). Overall, 55% (198/363) of cases with UPSIT <15th percentile and DAT‐SPECT <100% had positive aSynSAA, which increased to 70% (182/260) when selecting for more severe hyposmia (UPSIT <10th percentile).Interpretation: Remote screening for hyposmia and reduced DAT‐SPECT binding identifies participants with a high proportion positive aSynSAA. Longitudinal data will be essential to define progression patterns in these individuals to ultimately inform recruitment into disease modification clinical trials. ANN NEUROL 2025;97:730–740Keywords
All Related Versions
Funding Information
- Michael J. Fox Foundation for Parkinson's Research (MJFF‐022651)
This publication has 39 references indexed in Scilit:
- Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to SynucleinopathyAnnals of Neurology, 2024
- Clinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐upMovement Disorders, 2020
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohortAnnals of Clinical and Translational Neurology, 2018
- Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal CohortJAMA Neurology, 2017
- A single‐question screen for rapid eye movement sleep behavior disorder: A multicenter validation studyMovement Disorders, 2012
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- Association of olfactory dysfunction with risk for future Parkinson's diseaseAnnals of Neurology, 2008
- The REM sleep behavior disorder screening questionnaire—A new diagnostic instrumentMovement Disorders, 2007
- Association of olfactory dysfunction with incidental Lewy bodiesMovement Disorders, 2006
- Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUTMovement Disorders, 2004